Clinical trials located in

Murcia

Murcia city is located in Spain. Currently, 20 clinical trials are being conducted in this city.

Murcia, located in southeastern Spain, is the capital of the region bearing the same name. Founded by the Moors in 825 AD, it boasts a rich history evident in its architecture, including the stunning Cathedral of Murcia, which blends Gothic and Baroque styles. The city is also known for its vibrant festivals, notably the Spring Festival following Easter. Murcia is surrounded by fertile land, contributing to its reputation for producing a variety of fruits and vegetables, particularly lemons and oranges. The Segura River runs through the city, adding to its picturesque scenery.

  • CT-EU-00119886

    Study of Povetacicept for treating autoimmune blood disorders

    This clinical study aims to evaluate the safety and potential benefits of a drug called povetacicept in adults with autoimmune cytopenias, specifically immune thrombocytopenia, autoimmune hemolytic anemia, and cold agglutinin disease. The study is open-label, meaning both the researchers and participants know what treatment is being administered. Participants will receive povetacicept through a subcutaneous injection approximately every four weeks for six months. There is also a possibility of extending the treatment for an additional six months. The primary goal is to monitor the type, incidence, severity, and seriousness of any adverse events from the first day of treatment through 30 days after the last dose. This study is designed to determine if povetacicept is safe and potentially beneficial in treating these autoimmune conditions.

    • povetacicept
  • Study on the effectiveness and safety of Ianalumab for treating Warm Autoimmune Hemolytic Anemia

    This clinical trial is designed to evaluate the efficacy and safety of a drug called ianalumab in patients with warm autoimmune hemolytic anemia (wAIHA) who have not responded to at least one previous treatment. The study aims to determine if ianalumab can induce and maintain a durable hemoglobin response compared to a placebo.

    Participants will be randomly assigned to receive one of two different doses of ianalumab or a placebo. If a participant assigned to the placebo group does not respond to the treatment, they may be given ianalumab in an open-label manner, meaning both the participant and the doctor will know they are receiving the drug.

    The investigational treatment will be administered through an intravenous (i.v.) infusion. During the study, participants will have regular visits every other week during the treatment period and primary endpoint follow-up period. For safety monitoring, visits will occur monthly for the first 20 weeks after the last dose and then quarterly for up to two years. If a participant achieves a durable response, additional monthly visits for efficacy will continue for the first two years after the last dose, followed by quarterly visits until the loss of response or the end of the study, which could be up to 39 months after the last participant is randomized.

    The primary goal is to see if ianalumab can achieve a durable hemoglobin response, defined as a hemoglobin level of at least 10 g/dL and an increase of at least 2 g/dL from baseline for a period of at least eight consecutive weeks between weeks 9 and 25, without the need for rescue medication or prohibited treatment.

    This study offers hope for patients with wAIHA who have not found success with other treatments, providing a potential new option to manage their condition.

    • placebo
  • Study on combining two drugs – Fianlimab and Cemiplimab in patients with previously untreated melanoma

    This study examines two drugs, fianlimab and cemiplimab, given together for the treatment of melanoma. The main goal is to see how effective this drug combination is in treating melanoma compared with pembrolizumab, which is already approved for the treatment of melanoma in adults. The study will also look at whether there are any differences in the effects of these experimental drugs in adolescents and adults.

    Scientists also want to learn about other key issues: what side effects may occur from taking these experimental drugs, how much of the drugs enter the bloodstream over time, and whether the body produces antibodies to the drugs that could make them less effective or cause side effects. They will also check whether taking medications improves patients’ quality of life. Fianlimab and cemiplimab will be administered by intravenous infusion, and pembrolizumab will be administered by intravenous infusion.

    • placebo
    • Fianlimab
    • Cemiplimab
    • Pembrolizumab
  • Study of Selinexor Combined with Ruxolitinib for Myelofibrosis

    This here clinical trial is studying a new combination of drugs for treating myelofibrosis, which is a type of blood cancer. The main drugs being tested are selinexor and ruxolitinib. Selinexor is a new experimental drug that works by blocking the export of certain proteins from the cell nucleus, while ruxolitinib is an approved drug that inhibits JAK enzymes involved in myelofibrosis.

    The trial has two phases. The first phase, which is already completed, looked at finding the safest and most effective doses of selinexor when combined with ruxolitinib. The second phase is where they are actually testing this drug combination in patients with myelofibrosis who have not received any prior JAK inhibitor treatment.

    Patients in this phase will be randomly assigned to receive either the selinexor + ruxolitinib combination, or a placebo plus ruxolitinib alone. The main goals are to see if the combination can reduce spleen size by at least 35% after 24 weeks of treatment, and also improve symptoms like fatigue, itching, and abdominal discomfort by at least 50% on a special myelofibrosis symptom scale. Safety will also be closely monitored throughout the study.

    • Selinexor
    • Ruxolitinib
  • Study on the Safety and Effectiveness of INCB057643 for Myelofibrosis and Other Myeloid Neoplasms

    This clinical trial is focused on evaluating the safety, tolerability, and initial effectiveness of a medication called INCB057643, either on its own or in combination with another drug known as ruxolitinib. It is designed for participants who are dealing with myelofibrosis or other advanced myeloid neoplasms, which are types of blood disorders. The study aims to understand how well participants can handle the treatment and to observe any potential benefits or side effects that may occur during the trial. The treatment’s impact will be measured by monitoring the number of treatment-related adverse events, which includes any new or worsening symptoms following the start of the medication. This study is an important step towards finding new treatment options for individuals with myelofibrosis and related conditions, offering hope for better management of these diseases.

    • INCB057643
    • Ruxolitinib
  • Studying rilzabrutinib for chronic immune thrombocytopenia

    The research is underway to evaluate the efficacy and safety of a medication called rilzabrutinib in adults and teenagers with Immune Thrombocytopenia (ITP), a chronic blood condition characterized by a low platelet count. Participants will receive either the medication or a placebo twice daily over a period of about a year and a half. Platelet levels, overall health, and quality of life will be measured before and during the study to gather comprehensive data.

    • Rilzabrutinib
  • Testing the effectiveness and safety of povorcitinib in Asthma control

    This study involves an investigation into a medication known as povorcitinib, aimed at assessing its potential benefits for individuals with moderate to severe asthma whose current management is inadequate. The study adopts a ‘double-blind’ approach, ensuring that neither the participant nor the doctor is aware of whether the individual is receiving the actual drug or a placebo – a treatment resembling the drug but lacking any active substance. The focus lies in observing the impact of povorcitinib on lung function over a period of up to 24 weeks, with particular attention to the potential exacerbation of asthma symptoms.

    • povorcitinib
    • ICS-LABA
  • New therapy trial for relapsed large B-cell lymphoma

    This study is testing the use of two different treatments for diffuse large B-cell lymphoma (DLBCL), a type of blood cancer. Group One receives a mix of drugs, including polatuzumab vedotin, rituximab, ifosfamide, carboplatin, and etoposide (collectively called Pola-R-ICE). Group Two receives a similar mix without polatuzumab vedotin, known as R-ICE. Patients will be randomly sorted into the two groups. The test treatment spans three months and includes three chemotherapy treatments. After that, doctors will follow up with patients for at least 21 months. The goal is to compare how well the two treatments work to control DLBCL. Different factors, like progress of the disease, the response to treatment, and overall health will be observed to determine how efficient these treatments are.

    • Mabthera
    • Ifosfamide
    • Polatuzumab vedotin
    • Etoposide
    • Carboplatin
  • Comparison of different drug combinations in the treatment of relapsed mantle cell lymphoma

    In this trial, Glofitamab will be tested on patients with mantle cell lymphoma that has either recurred or not responded to prior therapy. The effectiveness of this medicine will be compared to alternative treatments suggested by physicians, such as a rituximab and bendamustine mix or a combination of lenalidomide and rituximab. Participants will be asked questions about their physical and emotional well-being, ability to handle day-to-day responsibilities, cognitive function, social lifestyle, symptoms like tiredness, vomiting, pain, etc., and overall health condition and life quality.

    • Tocilizumab
    • Obinutuzumab
    • Glofitamab
    • Bendamustine
    • Lenalidomide
    • Rituximab
  • Advanced lung cancer treatment: comparing osimertinib with standard chemotherapy

    In this extended study, researchers are evaluating two treatment approaches for non-small cell lung cancer (NSCLC), focusing on patients who have experienced disease progression extracranially after initial treatment with osimertinib. The study aims to compare the efficacy and safety of chemotherapy combined with osimertinib versus chemotherapy combined with a placebo. Patients are randomly assigned to one of two groups. Group A receives osimertinib daily along with two chemotherapy drugs (cisplatin or carboplatin and pemetrexed) for four 21-day cycles. After these cycles, they continue taking osimertinib with maintenance pemetrexed. Group B follows a similar protocol but with a placebo instead of osimertinib. The study’s objective is to understand which treatment method better helps patients with this specific cancer profile, considering factors like genetic mutations and the presence of brain metastases. By observing the treatment’s impact on disease progression and patient safety, the researchers hope to gain insights that could improve NSCLC treatment strategies.

    • AZD9291 (Osimertinib)
    • Cisplatin
    • Carboplatin
    • Pemetrexed
  • Study relating to new treatment for ovarian cancer

    This is a study for patients who have ovarian, fallopian tube, or primary peritoneal cancer that has resisted platinum-based treatments. The main goal is to see how well two drugs, Nemvaleukin Alfa and Pembrolizumab, work together compared to other chemotherapy treatments that the doctor chooses. Patients will be picked randomly by a computer to receive either the two-drug combo, one of the two drugs alone, or other chemo drugs, such as doxorubicin, paclitaxel, topotecan, or gemcitabine. This study is open, which means everyone will know which treatment is being given.

    • Nemvaleukin
    • Pegylated Liposomal Doxorubicin
    • Pembrolizumab
    • topotecan
    • Gemcitabine
    • Paclitaxel
  • Use of tucatinib in combination therapy for HER2-positive breast cancer

    This study examines whether tucatinib, combined with other medications, is more effective than a placebo in treating HER2-positive breast cancer. The research will also identify any side effects from the drug combination. Participants in this study have advanced breast cancer that is either unresectable (cannot be surgically removed) or metastatic (spread throughout the body). Participants will be randomly assigned to receive either tucatinib or a placebo, without knowing which one they are receiving. This method ensures the study’s fairness and accuracy. Additionally, all participants will receive trastuzumab and pertuzumab, two drugs effective against this cancer type. These will be administered every 21 days, either intravenously or subcutaneously, depending on the specific drug and combination used. The study has two main groups: one receiving a placebo and the other tucatinib, both alongside trastuzumab and pertuzumab.

    • Pertuzumab
    • Tucatinib
    • Trastuzumab
  • Testing resiniferatoxin injection for knee pain relief in osteoarthritis

    This study is about a medical product called Resiniferatoxin (RTX-GRT7039). The researchers want to know if a one-time injection of this product can help adults who have knee pain because of a condition called osteoarthritis. The researchers will compare the results with a group of people who get a placebo. Participants won’t know whether they’re getting the real product or the placebo. The study will last about a year. It will be measured in pain level, difficulty doing physical activities, and stiffness.

    • Resiniferatoxin/RTX-GRT7039
  • Testing mavacamten for heart muscle disease

    This study aims to assess a drug called Mavacamten for a heart condition called Non-Obstructive Hypertrophic Cardiomyopathy. Patients will be randomly given either the actual drug or a placebo without anyone knowing which one they’ve received. The study will measure how safe and effective the drug is for patients with symptoms of this heart condition. The success of the drug will be determined by preventing heart-related issues such as heart attacks, strokes, heart failures, irregular heartbeats, and the need for a heart-rhythm controlling device.

    • Mavacamten
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Examining new treatment for digestive complications of Graft Versus Host Disease

    This study is examining the effects of a therapy called MaaT013 in patients who do not respond well to a drug called Ruxolitinib. Patients suffer from a disease called acute GVHD that affects their stomach. Previous studies have shown promising results, with most patients showing improvement after receiving MaaT013. Due to these results, MaaT013 will be used as “rescue therapy” in patients who do not improve with steroids or JAK inhibitors, drugs often used to treat the disease. The standard first treatment for acute GVHD is steroids, but some patients do not respond well to this treatment, and those who do may have serious side effects if they take high doses for a long time. Therefore, scientists are interested in exploring alternative treatments such as MaaT013. A drug called Ruxolitinib was approved by the FDA in 2019, but again, not all patients respond well to this treatment, prompting the need to develop alternatives.

    • MaaT013- new potential medication for gastrointestinal acute graft-versus-host disease
  • Study on Tolebrutinib’s ability to delay disability progression in multiple sclerosis

    This is a study that involves a specific type of multiple sclerosis (MS) called primary progressive multiple sclerosis (PPMS). In this study, a drug called SAR442168, also known as Tolebrutinib, will be tested against a placebo. The main purpose of the study is to see if this drug can slow down the progression of disability in PPMS. The researchers will also look at the drug’s effect on clinical markers, brain images (MRI), thinking abilities, physical function, and quality of life. They will also consider the safety and tolerability of this drug. How long each person will take the drug can vary, but it will be somewhere between 12 and 60 months.

    • Tolebrutinib/SAR442168
  • Studying Ianalumab efficacy in primary immune thrombocytopenia

    This study is testing a drug called Ianalumab along with another drug called Eltrombopag to help people with a blood disease called primary immune thrombocytopenia, or ITP. ITP causes the body to destroy its platelets, which are needed to help the blood clot. Some people with ITP do not respond well to regular steroid treatment, so this study will test whether adding Ianalumab to Eltrombopag may help them more. Participants receive varying doses of Ianalumab or placebo along with Eltrombopag, with the goal of increasing the time to treatment failure. The careful design of the study ensures precise evaluation of this potential new therapy, providing hope for improved treatment of ITP.

    • Ianalumab
    • Eltrombopag
  • Testing drug combinations in recurring multiple myeloma

    This is a type of research study where the researchers compare two different treatments for multiple myeloma, a type of cancer in your blood. In the study, people will be placed into different groups and receive either a combination of iberdomide, daratumumab, and dexamethasone, or another combination of daratumumab, bortezomib, and dexamethasone. The researchers want to check how well the cancer responds to these treatments and see which one works better.

    • Iberdomide
    • Dexamethasone
    • Bortezomib
    • Daratumumab

See more clinical trials in other cities in Spain:

.